Technical Data
APEX1 (DNA-(Apurinic or Apyrimidinic Site) Lyase, APEX Nuclease, APEN, Apurinic-apyrimidinic Endonuclease 1, AP Endonuclease 1, APE-1, REF-1, Redox Factor-1, APE, APE1, APEX, APX, HAP1, REF1)
Human apurinic (apyrimidinic) endonuclease:redox-factor 1 (APE/Ref-1) is involved in the repair of DNA damage as well as in the transcriptional regulation of genes. The repair function of the protein is located on its C-terminal region. Activation of transcription factors, which occurs via a redox-based mechanism, pertains to a approximately 6kD N-terminal fragment with Cys-65 being of essential importance. Ape1/ref-1 has been shown to stimulate the DNA binding activity of numerous transcription factors that are involved in cancer promotion and progression such as Fos, Jun, NFkB, PAX, HIF-1, HLF and p53. APE/Ref-1 is part of the cellular response to oxidative stress and protects cells from the genotoxic and cytotoxic effect of oxidizing agents. Thus, specific downmodulation of APE:Ref-1 activity in tumors might be considered as a novel therapeutic approach in tumor therapy.

Suitable for use in Western Blot. Other applications not tested.

Recommended Dilution:
Western Blot: 1-2ug/ml
Optimal dilutions to be determined by the researcher.

Positive Control:

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
PabIgGAffinity Purified
100ug-20CBlue IceHumanRabbit
Synthetic peptides corresponding to aa36-52 and 216-232 of human APE (KLH).
Purified by Protein G affinity chromatography.
Supplied as a liquid in PBS, 0.02% sodium azide.
Recognizes human APE-1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Jiricny J. Nature 415(6872):593-4 (2002). 2. Demple B, Herma T, Chen DS. Proc Natl Acad Sci USA 88: 11450-11454 (1991). 3. Fritz G.. Int J Biochem Cell Biol 32 (9): 925-9 (2000). 4. Evans AR, Limp-Foster M, Kelley MR. Mutat Res 461(2):83-108 (2000). 5. Puglisi F, Barbone F, Tell G, Aprile G, Pertoldi B, Raiti C, et al. Oncol Rep 9(1):11-17 (2002).